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Inhibition of angiogenesis and murine tumour growth by laminarin sulphate
R Hoffmanl,* DH Paper2, J Donaldson' and H Vogl2
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Summary LAM S5 is a polysulphated derivative of the glucan laminarin that inhibits basic fibroblast growth
factor (bFGF) binding and the bFGF-stimulated proliferation of fetal bovine heart endothelial (FBHE) cells.
This report demonstrates that LAM S5 has anti-angiogenic activity, as shown by inhibition of tubule formation
by endothelial cells cultured on Matrigel and inhibition of vascularisation of the chick chorioallantoic
membrane. In addition, LAM S5 caused a tumour growth delay of the murine RIF-1 tumour of 2.6 days
(P=0.01).
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Inhibition of tumour neovascularisation, or angiogenesis, is a
promising new strategy for the treatment of cancer (see Scott
and Harris, 1994 for recent review). Several polysulphated
carbohydrates, such as pentosan polysulphate (PPS), chitin
derivatives and the bacteria-derived DS-4152, are anti-
angiogenic and inhibit tumour growth in animal models
(Zugmaier et al., 1992; Murata et al., 1991; Tanaka et al.,
1989). At least some of the anti-tumour activities of these
compounds can be attributed to inhibition ofheparin-binding
angiogenic growth factors produced by tumour cells
(Zugmaier et al., 1992; Nakayama et al., 1993). We have
recently identified a highly sulphated derivative of the /3-1,3-
glucan laminarin, designated LAM S5 (molecular weight
12 kDa), which inhibits basic fibroblast growth factor
(bFGF) binding and the bFGF-stimulated proliferation of
fetal bovine heart endothelial (FBHE) cells (Hoffman et al.,
1995a). bFGF is a potent angiogenic factor and is present at
elevated levels in the urine of some cancer patients (Nguyen
et al., 1994). Elevated expression of bFGF is associated with
a poor prognosis for patients with pancreatic cancer
(Yamanaka et al., 1993). In this study we have evaluated
the anti-angiogenic and anti-tumour activities of LAM S5.
Materials and methods
Reagents
LAM S5 was prepared according to Alban et al. (1992) from
laminarin (Senn, Dielsdorf, Switzerland). The laminarin had
approximately 10% branching at C-6 and an average degree
of polymerisation of 35. Sulphation was carried out by
continuous addition of S03/pyridine complex dissolved in
N,N-dimethylformamide for 4 h at 80°C. Sulphate content of
LAM S5 was determined by conductivity (Casu and
Gennaro, 1975). The molecular weight of LAM S5 was
determined by conductivity (Casu and Gennaro, 1975) and
by gel permeation chromatography on a fast protein liquid
chromatography (FPLC) system (Pharmacia) with a Superose
12 column.
Matrigel was from Stratech Scientific Ltd (Bedfordshire,
UK). Tissue culture materials, excluding fetal calf serum
(FCS), were from Gibco BRL (Paisley, UK). Serum, growth
factors and other reagents were from Sigma (Poole, UK).
Tissue culture
Fetal bovine heart endothelial (FBHE) cells were grown in
gelatinised flasks (0.1% gelatin for 2 h) in Dulbecco's
Modified Eagle medium (DMEM) 10% FCS, and were
supplied with bFGF (10 ng ml-1 every other day). The
human microvascular endothelial cell line CDC/EU.HMEC-1
(HMEC-1) (Ades et al., 1992) was kindly supplied by Dr E
Ades (Atlanta, GA, USA). HMEC-1 cells were cultured in
MCDB 131 medium supplemented with 10% FCS,
10 ng ml-1 epidermal growth factor (EGF) and 1 ig ml-1
hydrocortisone. RIF-I (radiation-induced fibrosarcoma) cells
were maintained according to the protocol of Twentyman et
al. (1980). All media contained antibiotics (100 units ml-
penicillin and 100 jug ml-' streptomycin).
Endothelial cell tubule formation
Endothelial cells (104 cells/well) were suspended in medium
and added to Matrigel (37 Ml/well) which had been allowed to
gel in 96-well plates. Test agent was added and the cells were
incubated at 37°C. Cells were examined 12 h later.
Experiments were performed in triplicate.
Chorioallantoic membrane (CAM) assay
A modification of a method for the shell-less cultivation of
chick embryo was used (Jakobson et al., 1989). Fertilised hen
eggs were incubated for 3 days (37°C, 80% humidity). The
eggs were then cracked into plastic cradles and 3 days later
test compound (in an agarose pellet) was added. The CAMs
were examined after a further 1 day. Pellets surrounded by
zones of inhibition of vascularisation were scored as positive
for inhibition of angiogenesis.
In vitro inhibition of RIF-J cells
RIF-I cells were plated down overnight in 96-well plates (103
per well) and treated with LAM S5. Cell numbers were
determined by an MTT assay 4 days later (Hoffman et al.,
1995b).
In vivo inhibition of RIF-J cells
RIF-1 cells (4 x 105) were injected subcutaneously on the right
flank of male C3H/Km mice (day 0). LAM S5 in 0.1 ml of
saline was injected intravenously commencing on day 1
(13 mg kg-'; daily 5 days week-'). Tetrahydrocortisol (THC)
was administered intraperitoneally commencing on day 1
using a tapering dose of 250 mg kg-1 for 4 days,
100 mg kg-1 for 3 days, 50 mg kg-1 for 4 days and
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1 mg kg-1 thereafter. Melphalan (formulated according to assay for inhibitors of angiogenesis (Folkman and Klagsbrun,
Honess and Bleehen, 1985) was injected as a single dose 1987). Pellets (10 l g) of LAM S5 inhibited CAM formation
(5 mg kg-') intraperitoneally on day 3. Tumours were on 80% of the eggs (Table I). Pellets (50 ,g) of LAM S5
measured in three dimensions (a, b, c) and tumour volumes
were calculated according to the formula
,- Lho Y/ :r (aoc A Jl
6
Tumour growth delays, defined as the time in days for
treated tumours to reach 300 mm3 compared with saline
controls, were determined from the geometric means of
individual tumour growth times and P-values were estimated
for a two-tailed t-test. All experiments were carried out in
compliance with the UKCCCR guidelines on welfare of
animals in research (1988).
Results and discussion
The structure of LAM S5 used in this study is shown in
Figure 1. The LAM S5 had a degree of sulphation (average
number of sulphates per sugar residue) of 2.31 and a
molecular weight determined by conductivity (Casu and
Gennaro, 1975) of approximately 12 500 da. The molecular
weight determined by gel permeation chromatography was
approximately 20 000 da, but this is probably an over-
estimate owing to effects of the hydrodynamic volume of
LAM S5.
Anti-angiogenic activity of LAM S5 was first evaluated by
examining the effect on tubule formation by endothelial cells
cultured on the basement membrane material Matrigel. This
procedure is an in vitro model, which reproduces some of the
features of angiogenesis. However, the early steps of
angiogenesis-degradation of existing basement membrane,
migration through the stromal space and proliferation-are
not represented by Matrigel tubule model. Rather, this model
represents the later stages of angiogenesis including cell
migration and tubule formation. Inhibition of tubule
formation by endothelial cells on Matrigel is frequently used
to identify agents which may have anti-angiogenic activity
(Scott and Harris, 1994; Candal et al., 1994). Migration of
the human microvascular endothelial line HMEC-1 was
evident 1-2 h after plating on Matrigel, and networks of
tubules formed by 8-12 h (Figure 2a). LAM S5 inhibited
tubule formation in a dose-dependent manner: 3 Mg ml-'
LAM S5 prevented the formation of complete networks of
tubules and 30 Mg ml-1 LAM S5 prevented most of the
tubule formation although some cells still migrated and formed clumps(Figure2b and c). Simla reslt w...e.r...e
formed clumps (Figure 2b and c). Similar results were
1. ...<.......................... . . . c obtained with the bovine macrovascular endothelial line
FBHE (data not shown).
The anti-angiogenic activity of LAM S5 was further
evaluated in the chick chorioallantoic membrane (CAM)
assay. This assay, initially developed by Folkman (1975) to
study tumour-induced angiogenesis, is now widely used as an
Figure 2 Inhibition of tubule formation by HMEC-1 cells by
LAM S5. (a) Control; (b) 3jigml-1 LAM S5; (c) 30 ,ug ml-1
Figure 1 Structure of LAM S5. LAM S5. Cells were plated on Matrigel and observed 12h later.
"resulted in inhibition of angiogenesis on all the eggs tested,
but this concentration of LAM S5 was associated with
increased toxicity to the chick embryos (Table I). Suramin,
which has anti-angiogenic activity (Pesenti et al., 1992) and
was used as a positive control in our studies, had less anti-
angiogenic activity than LAM S5 (Table I).
Several polysulphated carbohydrates with anti-angiogenic
activity have also been shown to inhibit tumour growth in
animal models (see introduction). LAM S5 was not well
tolerated in mice when administered intraperitoneally and
caused haemorrhagic deaths. The anticoagulant activity of
LAM S5 is probably due to the structural similarity of this
compound with heparin. Anticoagulant activity was the dose-
limiting toxicity in a recently reported phase I trial with the
polysulphated carbohydrate PPS (Pluda et al., 1993). We
have estimated, based on the activated partial thromboplastin
time (APTT) test, that a maximum plasma concentration of
9.5 jig ml-' LAM S5 is achievable before there is a
significant effect on the coagulation system (Hoffman et al.,
1995a). LAM S5 was better tolerated when given intrave-
nously. The maximum tolerated dose of LAM S5 given by
this route was about 13 mg kg-' on a schedule of
5 x daily week-'. We used this regimen to evaluate the anti-
tumour activity of LAM S5 against the murine tumour RIF-
1. In the first experiment, LAM S5 was administered alone
and in combination with the corticosteroid tetrahydrocortisol
(THC). Corticosteroids combined with heparin were shown
by Folkman to have anti-angiogenic and anti-tumour activity
(Folkman et al., 1983; Crum et al., 1985), and subsequent
studies have shown that the anti-tumour activity of some
anti-angiogenic heparin-like molecules is enhanced by
corticosteroids (Tanaka et al., 1989; Thorpe et al., 1993).
LAM S5 alone produced a statistically significant growth
delay of RIF-1 tumours relative to control values of about 3
days (Figure 3a and Table II). A combination of THC with
LAM S5 produced a growth delay of about 5 days, although
this increase in growth delay was not statistically significant
relative to LAM S5 alone (Figure 3a and Table II). THC
alone had no effect on RIF-1 tumour growth. None of the
mice receiving LAM S5, THC or the combination experi-
enced any toxicities or had any significant weight loss (data
not shown). THC has no glucocorticoid or mineralocorticoid
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activities and thus avoids the toxicity problems of some
corticosteroids (unpublished observations; Penhaligon and
Camplejohn, 1985).
Anti-angiogenic agents have been reported to potentiate
the anti-tumour activities of some cytotoxic drugs (Teicher et
al., 1992). Therefore, we studied the effect of LAM S5 in
combination with the alkylating agent melphalan. Melphalan
has previously been shown to inhibit RIF-l tumours (Honess
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Figure 3 Anti-tumour activity of LAM S5 against the RIF-1
murine tumour. (a) LAM S5 (13mgkg-1; daily 5 days week-')
(0) or tetrahydrocortisol (tapering dose of 250 mgkg- 1 to
1 mgkg-1) ([1) were administered alone or in combination (U).
(b) LAM S5 (13mgkg-1; daily 5 days week -) (@) or melphalan
(5mgkg-'; single dose) (AL) were administered alone or in
combination (A). Further details in Materials and methods. (0),
saline control. Bars represent s.e.
Table II Growth delay of the RIF-1 tumour by LAM S5 alone and combined with tetrahydrocortisol or
melphalan
Growth delaya (geometric
Treatment mean and ranges on mean) P value (test vs control)
Experiment 1
LAM S5 (n=5) 3.3 (2.2-3.5) 0.002
Tetrahydrocortisol (n=5) 0.7 (-0.5-2.6) 0.41
LAM S5/tetrahydrocortisol (n=5) 4.8 (2.3-7.7) 0.005
Experiment 2
LAM S5 (n=5) 2.0 (0-4.3) 0.20
Melphalan (n=7) 2.2 (0.5-4.1) 0.13
LAM S5/melphalan (n=7) 6.1 (2.5-10.5) 0.01
Experiments 1 and 2
LAM S5 (n = 10) 2.6 (1.5-3.9) 0.01
aTime in days for treated tumours to reach 300 mm3 compared with saline controls.Anti-angiogenic and anti-tumour laminarin sulphate
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(13 mg kg-'; daily 5 days week-') and a single dose of
melphalan administered intraperitoneally (5 mg kg-') both
produced tumour growth delays of about 2 days, but these
values are not statistically significant relative to controls
(Figure 3b and Table II). A combination of melphalan and
LAM S5 resulted in a growth delay of 6 days and this was
statistically significant relative to control values (Figure 3b
and Table II). No toxicity or weight loss was observed in
mice treated with the combination of melphalan and LAM
S5. However, two of seven mice died early on (days 7 and 14)
in the LAM S5 group. Post-mortems revealed haemorrhaging
in the peritoneal cavities.
In summary, these results demonstrate that the poly-
sulphated glucan LAM S5 inhibits angiogenesis and has anti-
tumour activity against the RIF-I tumour. The overall
tumour growth delay by LAM S5 is 2.6 days (P=0.01)
when data from the two in vivo experiments are pooled
(Table II). Combining LAM S5 with a corticosteroid or a
cytotoxic agent resulted in a slight increase in anti-tumour
activity. At present we have not established if the anti-
tumour activity of LAM S5 is due to inhibition of tumour
neovascularisation or to a more direct effect on RIF-1 cells.
However, endothelial cells are inhibited at a lower
concentration of LAM S5 than RIF-l cells since the IC50
value for inhibition of the proliferation of the endothelial
line FBHE is 1 ig ml-' LAM S5 (Hoffman et al., 1995a),
and 3 ig ml-' LAM S5 starts to inhibit tubule formation of
endothelial cells (present results), whereas the proliferation of
RIF-I cells in vitro is inhibited with an IC50 of 30 jug ml-'
(data not shown). The activity of LAM S5 against other
tumours remains to be evaluated. LAM S5 represents a useful
lead molecule for developing lower molecular weight
derivatives as it is structually a simple polysaccharide
composed only of glucose with mainly /1-1,3 linkages
between the sugars.
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